POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding
POP Biotechnologies has secured $9.7 million in funding from the Coalition for Epidemic Preparedness Innovations. The capital will support Phase 1 clinical trials for their SNAP nanoparticle vaccine platform.
Why it matters
Advancements in nanoparticle vaccine technology are critical for rapid response to future global health threats.
POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding Sign In New user? Click Here Subscribe Sign In New user? Click Here OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS BUSINESS FORUM PODCASTS RESOURCES WEATHER MARKET OVERVIEW The Manila Times 500 EXAM RESULTS TMT DIGITAL EDITION TMT CSI TMT 127TH ANNIVERSARY QUIZZES GAMES more OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS BUSINESS FORUM PODCASTS RESOURCES WEATHER MARKET OVERVIEW The Manila Times 500 EXAM RESULTS TMT DIGITAL EDITION TMT CSI TMT 127TH ANNIVERSARY QUIZZES GAMES OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS BUSINESS FORUM PODCASTS RESOURCES WEATHER MARKET OVERVIEW The Manila Times 500 EXAM RESULTS TMT DIGITAL EDITION TMT CSI TMT 127TH ANNIVERSARY QUIZZES GAMES TMT Newswire GlobeNewswire POP Biotechnologies Secures Up to $9.7 Million in CEPI Funding By GlobeNewswire June 4, 2026 Resize Small Medium Large Funding to Propel POP BIO SNAP™ Nanoparticle Vaccine Platform into Phase 1 Clinical Trials in the U.S.
The article is a factual report on corporate funding and clinical trial progress.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in